Table 4.

Reduction of primary AML by AbTCR and AbTCR-CSR T cells

Primary AMLReduction of CD33+ cells (%)HLA-A∗02:01WT1 RMF/HLA-A2 complex expressionCD33 expression
CSR onlyAbTCR no. 18 onlyAbTCR no. 34 onlyAbTCR-CSR no. 18AbTCR-CSR no. 34
60D None 73 28 90 16 99% 
114B None 35 38 81 17 54% 
92C None 57 69 69 74 77% 
120B None 5.6 None None 2.3 − − 40% 
AML-14 None 41 55 74 55 99% 
Primary AMLReduction of CD33+ cells (%)HLA-A∗02:01WT1 RMF/HLA-A2 complex expressionCD33 expression
CSR onlyAbTCR no. 18 onlyAbTCR no. 34 onlyAbTCR-CSR no. 18AbTCR-CSR no. 34
60D None 73 28 90 16 99% 
114B None 35 38 81 17 54% 
92C None 57 69 69 74 77% 
120B None 5.6 None None 2.3 − − 40% 
AML-14 None 41 55 74 55 99% 

Primary AML samples were labeled with either CFSE or far-red and coincubated with ESK2 AbTCR or AbTCR-CSR T cells at an effector-to-target ratio of 1:1, overnight. The cells were harvested and were stained with anti-CD33 mAb and analyzed by flow cytometry. The cells were gated on live cells and the same gates were applied to all groups. The percentage of CD33 and CFSE-positive (or far-red–positive) cells in the live cell gates were analyzed (as shown in supplemental Figure 6), and the percentage of total CD33+CFSE/far-red+ cells were calculated (including CD33low cells in AbTCR-CSR groups).

Percentage reduction of the AML cells by AbTCR, AbTCR-CSR T cells was calculated by comparison with mock T cells. HLA-A2, and CD33 expression were measured by flow cytometric analysis.

WT1 expression was assessed by ESK1 and ESK2 staining. AML-14 is a positive control AML cell line.

+, ≥1.5-fold increase over the isotype control staining for WT1 RMF/HLA-A2; +, ≥20 fold over isotype for HLA-A2 and CD33; and none, 0% to 1.5% reduction over mock T-cell groups.

Close Modal

or Create an Account

Close Modal
Close Modal